Genetic and molecular advances in Alzheimer's disease
- PMID: 7504354
- DOI: 10.1016/0166-2236(93)90007-9
Genetic and molecular advances in Alzheimer's disease
Abstract
The abnormal deposition of amyloid beta protein (A beta) in the brain is the major neuropathological characteristic of Alzheimer's disease (AD). The disease in some early-onset familial cases develops as a result of mutations in the gene coding for the beta-amyloid precursor protein (beta APP) and in the majority of the rest appears to be caused by an unidentified gene on chromosome 14. Only one of the beta APP gene mutations has been associated with aberrant beta APP processing, resulting in an excess production of A beta in vitro, a result suggesting that there might be excessive A beta cleavage from beta APP in AD in vivo. By contrast with the beta APP mutants, no particular allele of the apolipoprotein E (APOE) gene predicts the disease completely but one allele is associated with the disease suggesting APOE is a risk locus for AD. This discovery has been linked to increased deposition of A beta in those cases carrying the risk allele. However, the genetic evidence is currently not sufficient to indicate whether beta APP mismetabolism, direct or indirect A beta neurotoxicity or dysfunction of beta APP (or its derivatives) are central to the AD process.
Similar articles
-
The molecular genetics of Alzheimer's disease.Mol Neurobiol. 1994 Aug-Dec;9(1-3):15-22. doi: 10.1007/BF02816100. Mol Neurobiol. 1994. PMID: 7888092 Review.
-
The role of the amyloid protein precursor (APP) in Alzheimer's disease: does the normal function of APP explain the topography of neurodegeneration?Neurochem Res. 1998 May;23(5):795-806. doi: 10.1023/a:1022471729291. Neurochem Res. 1998. PMID: 9566620 Review.
-
Autosomal-dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Aβ production.J Neurochem. 2014 Jan;128(2):330-9. doi: 10.1111/jnc.12466. Epub 2013 Oct 24. J Neurochem. 2014. PMID: 24117942
-
Molecular genetics of Alzheimer's disease.Aging (Milano). 1993 Dec;5(6):417-25. doi: 10.1007/BF03324196. Aging (Milano). 1993. PMID: 8161573 Review.
-
Glutamate, beta-amyloid precursor proteins, and calcium mediated neurofibrillary degeneration.J Neural Transm Suppl. 1994;44:29-45. doi: 10.1007/978-3-7091-9350-1_3. J Neural Transm Suppl. 1994. PMID: 7897398 Review.
Cited by
-
The molecular significance of amyloid beta-peptide for Alzheimer's disease.Eur Arch Psychiatry Clin Neurosci. 1996;246(3):118-23. doi: 10.1007/BF02189111. Eur Arch Psychiatry Clin Neurosci. 1996. PMID: 8739395 Review.
-
Paired helical filament tau in Alzheimer's disease. The kinase connection.Am J Pathol. 1994 Mar;144(3):449-53. Am J Pathol. 1994. PMID: 8129030 Free PMC article. Review. No abstract available.
-
Regressive Autism Spectrum Disorder: High Levels of Total Secreted Amyloid Precursor Protein and Secreted Amyloid Precursor Protein-α in Plasma.Front Psychiatry. 2022 Mar 8;13:809543. doi: 10.3389/fpsyt.2022.809543. eCollection 2022. Front Psychiatry. 2022. PMID: 35350428 Free PMC article.
-
Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the store.Aging Cell. 2007 Jun;6(3):307-17. doi: 10.1111/j.1474-9726.2007.00295.x. Epub 2007 Apr 26. Aging Cell. 2007. PMID: 17465978 Free PMC article. Review.
-
Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation.J Neurosci. 1997 Feb 1;17(3):1046-54. doi: 10.1523/JNEUROSCI.17-03-01046.1997. J Neurosci. 1997. PMID: 8994059 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
